APRI (Aprinoia Therapeutics) Interest Expense: $-4.02 Mil (TTM As of Dec. 2023)


What is Aprinoia Therapeutics Interest Expense?

Aprinoia Therapeutics APRI Interest Expense is $-4.02 Mil as of Dec. 2023.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aprinoia Therapeutics's interest expense for the six months ended in Dec. 2023 was $ -2.58 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aprinoia Therapeutics's Operating Income for the six months ended in Dec. 2023 was $ -17.47 Mil. Aprinoia Therapeutics's Interest Expense for the six months ended in Dec. 2023 was $ -2.58 Mil. Aprinoia Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aprinoia Therapeutics  (NAS:APRI) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aprinoia Therapeutics's Interest Expense for the six months ended in Dec. 2023 was $-2.58 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-17.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $0.21 Mil.

Aprinoia Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Aprinoia Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Aprinoia Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Interest Expense Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Interest Expense
-0.04 -0.07 -4.02

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Interest Expense 0.00 -0.01 -0.05 -1.44 -2.58

Aprinoia Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-4.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-4.02 Mil mean?
Aprinoia Therapeutics (APRI) has a Interest Expense of $-4.02 Mil as of Dec. 2023. Interest Expense is the amount a company pays on its long-term debt. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Interest Expense too high?
Aprinoia Therapeutics' current Interest Expense is $-4.02 Mil.
How does Aprinoia Therapeutics' Interest Expense compare to ?
Aprinoia Therapeutics' Interest Expense of $-4.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Interest Expense is $-4.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Interest Expense of $-4.02 Mil. The current Interest Expense is $-4.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Interest Expense is $-4.02 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.